Australia markets open in 5 hours 10 minutes

Lexaria Bioscience Corp. (LEXX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
3.3500+0.2200 (+6.92%)
As of 02:49PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 40.33M
Enterprise value 35.69M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)66.69
Price/book (mrq)6.19
Enterprise value/revenue 88.18
Enterprise value/EBITDA -6.89

Trading information

Stock price history

Beta (5Y monthly) 0.95
52-week change 3192.68%
S&P500 52-week change 322.38%
52-week high 36.8500
52-week low 30.6490
50-day moving average 33.1791
200-day moving average 31.7461

Share statistics

Avg vol (3-month) 3509.03k
Avg vol (10-day) 3176.35k
Shares outstanding 512.89M
Implied shares outstanding 612.89M
Float 810.63M
% held by insiders 112.77%
% held by institutions 17.44%
Shares short (15 Apr 2024) 4435.58k
Short ratio (15 Apr 2024) 41.21
Short % of float (15 Apr 2024) 43.55%
Short % of shares outstanding (15 Apr 2024) 43.38%
Shares short (prior month 15 Mar 2024) 4754.51k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 312 Jan 2021
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Aug 2023
Most-recent quarter (mrq)29 Feb 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-460.69%

Management effectiveness

Return on assets (ttm)-59.36%
Return on equity (ttm)-101.49%

Income statement

Revenue (ttm)404.73k
Revenue per share (ttm)0.05
Quarterly revenue growth (yoy)624.10%
Gross profit (ttm)N/A
EBITDA -5.18M
Net income avi to common (ttm)-5.44M
Diluted EPS (ttm)-0.6700
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)4.79M
Total cash per share (mrq)0.37
Total debt (mrq)148.88k
Total debt/equity (mrq)2.42%
Current ratio (mrq)66.29
Book value per share (mrq)0.53

Cash flow statement

Operating cash flow (ttm)-5.21M
Levered free cash flow (ttm)-3.45M